ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.296,44
-0,01%
Dow Jones
39.895,97
0,07%
Euro vs US Dollar
1,08725
0,05%
Bitcoin
67.254,21
3,09%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Natera Inc (NTRA)

  7. Natera Inc (NTRA) News

NTRA

Natera (NTRA)

Natera Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NTRA
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202422h56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
11/05/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
11/05/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
11/05/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
11/05/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
11/05/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
11/05/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
10/05/202422h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
09/05/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTRANatera Inc
09/05/202422h05Business WireNatera Reports First Quarter 2024 Financial ResultsNASDAQ:NTRANatera Inc
04/05/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
03/05/202414h00Business WireNew Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast CancerNASDAQ:NTRANatera Inc
01/05/202422h05Business WireNatera to Report its First Quarter 2024 Results on May 9NASDAQ:NTRANatera Inc
01/05/202413h00Business WireNatera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg ShortageNASDAQ:NTRANatera Inc
22/04/202414h00Business WireNatera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsNASDAQ:NTRANatera Inc
11/04/202414h00Business WireNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationNASDAQ:NTRANatera Inc
08/04/202414h00Business WireNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant RecipientsNASDAQ:NTRANatera Inc
05/04/202413h00Business WireNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder CancerNASDAQ:NTRANatera Inc
01/04/202414h00Business WireNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial CancerNASDAQ:NTRANatera Inc
18/03/202412h00Business WireNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerNASDAQ:NTRANatera Inc
14/03/202413h00Business WireNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseNASDAQ:NTRANatera Inc
12/03/202413h00Business WireNatera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersNASDAQ:NTRANatera Inc
09/03/202402h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
08/03/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
 Showing the most relevant articles for your search:NASDAQ:NTRA

Kürzlich von Ihnen besucht

USOTC
ADDYY
Adidas (QX)
NASDAQ
GOOGL
Alphabet
TG
LHA
Deutsche Lufthansa
AMEX
XLV
Health Care Select Sector
NYSE
XOM
Exxon Mobil
COIN
ETHUSD
Ethereum
TG
DBK
Deutsche Bank
AMEX
XLF
Financial Select Sector
NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
TG
D7G
Nel ASA
FX
EURUSD
Euro vs US Dollar
CCOM
US100
US Tech 100
TG
BAS
BASF
CCOM
US500
US 500
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten